| abstract |
The present invention treats respiratory disorders, skin disorders, and allergic conjunctivitis associated with the production of mucus glycoproteins while substantially reducing the adverse effects associated with administration of non-selective anticholinergic agents. It relates to useful formulations and methods of use. In particular, the formulation contains a muscarinic acetylcholine receptor subtype M1 and / or M3 selective antagonist (eg, oxybutynin) in combination with one or more pharmaceutically active agents (eg, desloratidine). |